This finding aligns with NICE recommendations that require a consultation with a specialized clinician before prescribing symptomatic AD medications whereas APA guidelines state the cholinesterase inhibitors should be offered to patients with mild to moderate AD dementia [16, 17]. This evidence concerns the gene BCHE and Alzheimer disease.